» Articles » PMID: 456401

Pharmacokinetics of Quinidine Related to Plasma Protein Binding in Man

Overview
Specialty Pharmacology
Date 1979 Apr 17
PMID 456401
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

The disposition and plasma protein binding of quinidine after intravenous administration were studied in 13 healthy subjects. Plasma protein binding, expressed as the fraction of quinidine unbound ranged from 0.134--0.303 (mean 0.221). Elimination rate constant (beta) varied from 0.071 to 0.146 h-1 (mean 0.113), and apparent volume of distribution (Vbeta) varied from 1.39--3.20 1 . kg-1 beta (mean 2.27). Total body clearance was 2.32--6.49 ml min-1 . kg-1. There was a positive linear correlation between the plasma fraction of unbound quinidine and both V beta (r = 0.885, p less than 0.01) and total body clearance (r = 0.668, p less than 0.05). No significant correlation existed between the fraction of unbound quinidine in plasma and the elimination rate constant. The results show that both the apparent volume of distribution and total body clearance of quinidine are proportional to the unbound fraction in plasma. This implies that the total plasma concentration of quinidine at steady state will change with alterations in plasma binding, whilst the concentration of unbound compound and its elimination rate will remain unaffected.

Citing Articles

Disease-induced changes in the plasma binding of basic drugs.

Piafsky K Clin Pharmacokinet. 1980; 5(3):246-62.

PMID: 6156048 DOI: 10.2165/00003088-198005030-00004.


Analysis of nonlinear tissue distribution of quinidine in rats by physiologically based pharmacokinetics.

Harashima H, Sawada Y, Sugiyama Y, Iga T, Hanano M J Pharmacokinet Biopharm. 1985; 13(4):425-40.

PMID: 4087170 DOI: 10.1007/BF01061478.


Plasma protein binding of imipramine in patients with rheumatoid arthritis.

Kristensen C Eur J Clin Pharmacol. 1985; 28(6):693-6.

PMID: 4065195 DOI: 10.1007/BF00607918.


Prediction of the disposition of nine weakly acidic and six weakly basic drugs in humans from pharmacokinetic parameters in rats.

Sawada Y, Hanano M, Sugiyama Y, Iga T J Pharmacokinet Biopharm. 1985; 13(5):477-92.

PMID: 3938813 DOI: 10.1007/BF01059331.


The pharmacokinetics and pharmacodynamics of quinidine and 3-hydroxyquinidine.

Smalley J, Visco J, Slaughter R Br J Clin Pharmacol. 1988; 26(4):415-21.

PMID: 3190991 PMC: 1386563. DOI: 10.1111/j.1365-2125.1988.tb03400.x.


References
1.
Nilsen O . Serum albumin and lipoproteins as the quinidine binding molecules in normal human sera. Biochem Pharmacol. 1976; 25(9):1007-12. DOI: 10.1016/0006-2952(76)90488-3. View

2.
Kates R, SOKOLOSKI T, Comstock T . Binding of quinidine to plasma proteins in normal subjects and in patients with hyperlipoproteinemias. Clin Pharmacol Ther. 1978; 23(1):30-5. DOI: 10.1002/cpt197823130. View

3.
Ball R, SOKOLOW M . Factors influencing conversion of chronic atrial fibrillation with special reference to serum quinidine concentration. Circulation. 1956; 14(4 Part 1):568-83. DOI: 10.1161/01.cir.14.4.568. View

4.
Ueda C, Williamson B, Dzindzio B . Disposition kinetics of dihydroquinidine following quinidine administration. Res Commun Chem Pathol Pharmacol. 1976; 14(2):215-25. View

5.
Yacobi A, Udall J, Levy G . Serum protein binding as a determinant of warfarin body clearance and anticoagulant effect. Clin Pharmacol Ther. 1976; 19(5 Pt 1):552-8. DOI: 10.1002/cpt1976195part1552. View